| PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting HYJJZ Lauren M. Thorpe Nature Reviews Cancer 15 (1), 7–24, 2014 | 1390* | 2014 |
| Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors JJZ Shom Goel, Qi Wang, April C. Watt, Sara M. Tolaney, Deborah A. Dillon ... Cancer Cell 29 (3), p255–269, 2016 | 436 | 2016 |
| CDK7-dependent transcriptional addiction in triple-negative breast cancer Y Wang, T Zhang, N Kwiatkowski, BJ Abraham, TI Lee, S Xie, H Yuzugullu, ... Cell 163 (1), 174-186, 2015 | 433 | 2015 |
| Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells H Yuzugullu, K Benhaj, N Ozturk, S Senturk, E Celik, A Toylu, N Tasdemir, ... Molecular cancer 8, 1-20, 2009 | 305 | 2009 |
| Senescence and immortality in hepatocellular carcinoma M Ozturk, A Arslan-Ergul, S Bagislar, S Senturk, H Yuzugullu Cancer letters 286 (1), 103-113, 2009 | 118 | 2009 |
| Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. SP Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE ... Cancer Cell 31 (4), 576–590, 2017 | 96 | 2017 |
| Aflatoxin genotoxicity is associated with a defective DNA damage response bypassing p53 activation O Gursoy‐Yuzugullu, H Yuzugullu, M Yilmaz, M Ozturk Liver International 31 (4), 561-571, 2011 | 91 | 2011 |
| Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis G Yildiz, A Arslan-Ergul, S Bagislar, O Konu, H Yuzugullu, ... PloS one 8 (5), e64016, 2013 | 69 | 2013 |
| Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110α K Gritsman, H Yuzugullu, T Von, H Yan, L Clayton, C Fritsch, SM Maira, ... The Journal of clinical investigation 124 (4), 1794-1809, 2014 | 65 | 2014 |
| A PI3K p110β–Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis H Yuzugullu, L Baitsch, T Von, A Steiner, H Tong, J Ni, LK Clayton, ... Nature communications 6 (1), 8501, 2015 | 47 | 2015 |
| The ability to generate senescent progeny as a mechanism underlying breast cancer cell heterogeneity M Mumcuoglu, S Bagislar, H Yuzugullu, H Alotaibi, S Senturk, ... PloS one 5 (6), e11288, 2010 | 27 | 2010 |
| NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K–AKT and JAK–STAT3 pathways H Yuzugullu, T Von, LM Thorpe, SR Walker, TM Roberts, DA Frank, ... Cell discovery 2 (1), 1-13, 2016 | 22 | 2016 |
| Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma U Ekin, H Yuzugullu, C Ozen, P Korhan, E Bagirsakci, F Yilmaz, ... Journal of Gastrointestinal Cancer, 1-14, 2021 | 2 | 2021 |
| First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi … V Samnotra, V Moroz, L Shtessel, M Kuchimanchi, P Hanafin, ... Journal of Clinical Oncology 42 (16_suppl), TPS3174-TPS3174, 2024 | | 2024 |
| Abstract CT169: First-in-human, phase 1/2 study of GSK4524101, an oral DNA polymerase theta inhibitor (POLQi), alone or combined with the poly (ADP-ribose) polymerase (PARP … V Samnotra, V Moroz, L Shtessel, M Kuchimanchi, P Hanafin, ... Cancer Research 84 (7_Supplement), CT169-CT169, 2024 | | 2024 |
| Development of a second-generation TRAIL agonist and predictive biomarker profile for colorectal cancer S Ghassemifar, Y Hashambhoy-Ramsay, H Yuzugullu, T Utermark, ... Cancer Research 79 (13_Supplement), 700-700, 2019 | | 2019 |
| Methods for selecting and treating patients with a trail-based therapeutic or death receptor agonist D Tamara, S Ghassemifar, Y Hashambhoy-ramsay, DHC MARCANTONIO, ... US Patent App. 16/305,289, 2019 | | 2019 |
| INVESTIGATION OF CAUSATIVE AGENTS IN COMMUNITY-ACQUIRED ATYPICAL PNEUMONIA CASES E ÇALIŞKAN, Ş ÖKSÜZ, C ÖZTÜRK, I Sahin, O Kilincel, N Akar, ... FRESENIUS ENVIRONMENTAL BULLETIN 28 (5), 2019 | | 2019 |
| MM-161, a first-in-class pan-FGFR antibody T Dake, G Finn, M Geddie, N Kohli, M Razlog, L Xu, V Paragas, ... Cancer Research 77 (13_Supplement), 22-22, 2017 | | 2017 |
| Targeted Therapy for Hepatocellular Carcinoma: What`s New? H Yuzugullu, O Gursoy-Yuzugullu Liver Res Open J 1 (1), e1-e3, 2015 | | 2015 |
Mehmet OzturkIzmir Tinaztepe University在 tinaztepe.edu.tr 的电子邮件经过验证
